Jun Lei1, Zhi Zhou1. 1. Department of Neurosurgery, The First People's Hospital of Shuangliu District, Chengdu/West China (Airport) Hospital Sichuan University Chengdu 610200, Sichuan Province, China.
Abstract
OBJECTIVE: To determine the efficacy and safety of bevacizumab (Bz) combined with temozolomide (TMZ) in the treatment of recurrent malignant gliomas and its influence on serum tumor markers (STMs). METHODS: The clinical data of 73 patients with recurrent malignant gliomas admitted to the First People's Hospital of Shuangliu District from April 2016 to June 2018 were analyzed retrospectively. Patients were divided into two groups according to different therapies: the control group (n=33) treated with TMZ, and the research group (n=40) treated with Bz combined with TMZ (Bz+TMZ). The overall response rate (ORR), disease control rate (DCR) and incidence of adverse reactions (ARs) were observed after 4 courses of treatment. The levels of STMs were detected. Additionally, the Karnofsky Performance Scale (KPS) score and quality of life (QoL) before and after treatment were compared between the two groups. The 1-year and 2-year survival rates as well as median survival time (MST) were also compared after 2-year follow-up. Treatment satisfaction was recorded and compared. RESULTS: After treatment, the research group exhibited better ORR and DCR than the control group; The incidence of ARs differed insignificantly between the two arms; The serum levels of Vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and transforming growth factor β (TGF-β) in the research group were statistically lower than those in the control group; The KPS score and QoL score increased significantly in both arms, and were higher in the research group compared with the control group; the research group was also superior to the control group in treatment satisfaction. The research group showed higher 1-year and 2-year survival rates than the control group. CONCLUSIONS: BZ+TMZ is effective in treating recurrent malignant gliomas, which can improve the QoL and survival of patients. AJTR
OBJECTIVE: To determine the efficacy and safety of bevacizumab (Bz) combined with temozolomide (TMZ) in the treatment of recurrent malignant gliomas and its influence on serum tumor markers (STMs). METHODS: The clinical data of 73 patients with recurrent malignant gliomas admitted to the First People's Hospital of Shuangliu District from April 2016 to June 2018 were analyzed retrospectively. Patients were divided into two groups according to different therapies: the control group (n=33) treated with TMZ, and the research group (n=40) treated with Bz combined with TMZ (Bz+TMZ). The overall response rate (ORR), disease control rate (DCR) and incidence of adverse reactions (ARs) were observed after 4 courses of treatment. The levels of STMs were detected. Additionally, the Karnofsky Performance Scale (KPS) score and quality of life (QoL) before and after treatment were compared between the two groups. The 1-year and 2-year survival rates as well as median survival time (MST) were also compared after 2-year follow-up. Treatment satisfaction was recorded and compared. RESULTS: After treatment, the research group exhibited better ORR and DCR than the control group; The incidence of ARs differed insignificantly between the two arms; The serum levels of Vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and transforming growth factor β (TGF-β) in the research group were statistically lower than those in the control group; The KPS score and QoL score increased significantly in both arms, and were higher in the research group compared with the control group; the research group was also superior to the control group in treatment satisfaction. The research group showed higher 1-year and 2-year survival rates than the control group. CONCLUSIONS: BZ+TMZ is effective in treating recurrent malignant gliomas, which can improve the QoL and survival of patients. AJTR
Authors: Or Cohen-Inbar; Cheng-Chia Lee; Seyed H Mousavi; Hideyuki Kano; David Mathieu; Antonio Meola; Peter Nakaji; Norissa Honea; Matthew Johnson; Mahmoud Abbassy; Alireza M Mohammadi; Danilo Silva; Huai-Che Yang; Inga Grills; Douglas Kondziolka; Gene H Barnett; L Dade Lunsford; Jason Sheehan Journal: J Neurosurg Date: 2016-04-22 Impact factor: 5.115
Authors: Sam C Kwiatkowski; Paola A Guerrero; Shinya Hirota; Zhihua Chen; John E Morales; Manish Aghi; Joseph H McCarty Journal: PLoS One Date: 2017-09-22 Impact factor: 3.240
Authors: Kerstin A Kessel; Josefine Hesse; Christoph Straube; Claus Zimmer; Friederike Schmidt-Graf; Jürgen Schlegel; Bernhard Meyer; Stephanie E Combs Journal: PLoS One Date: 2017-07-05 Impact factor: 3.240